MXCT vs PTC · rev $38.6M vs P/E 48, rev $2.74B
MaxCyte Inc (MXCT) versus PTC Inc (PTC) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
PTC Inc (PTC) is a software - application company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported PTC revenue for 2025-09-30 was $2.74B. Net income was $734.0M. Revenue was up 19.2% from 2024-09-30 to 2025-09-30. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
MXCT currently screens at market cap $124.3M. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
Not investment advice. Open the MXCT and PTC stock pages for the full models.
Not investment advice.